THE WIRE · № 85283
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
01 THE MACHINE READ
WHY IT MATTERS.
Long-term IBD data support AbbVie's immunology franchise, reinforcing revenue durability rather than near-term catalysts.
Supports immunology franchise durability, not a near-term catalyst
Regulatory or label expansion decisions
Data is company-sponsored and promotional
FULL DISPATCH
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI®(risankizumab) and RINVOQ® (upadacitinib) provide additional insight into clinical and endoscopic outcomes over...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
Health savings accounts continue to gain ground with Americans—with good reason because they offer triple tax benefits2026-10-16 09:33 UTC
City Therapeutics surges in market debut after upsizing $200M IPO2026-10-16 17:13 UTC
City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver2026-10-16 17:48 UTC
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia2026-10-16 20:05 UTC
Eli Lilly buys about $12.3M in TRex Bio (TRXB) IPO shares, adding to its holdings.2026-10-16 20:19 UTC
AMCP Market Insights Findings Show Uncertainty in Biomarker Testing for ESR1-Mutated Advanced Breast Cancer as Payers Weigh Earlier Detection and a Growing Class of Targeted Therapies2026-10-16 21:03 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.